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Abstract
Objetives: Recurrent aphthous stomatitis (RAS) is a common pathology of the oral mucosa with a complex and 
multifactorial etiology. Tumour Necrosis Factor-alpha (TNFα) is a cytokine with an important but not well-known 
role in the development of new lesions in RAS patients. Modifications of salivary levels of TNFα in RAS patients 
during the active periods of the disease have been measured in this work. The possible implication of TNFα in 
RAS etiology is also discussed. Study design: The study group was composed of 20 patients previously diagnosed 
with RAS and randomly selected. As a control group 10 healthy patients were also randomly selected. In both 
groups a TNFα assessment was carried out in non stimulated saliva. All the patients in the study group presented 
active lesions at the moment of the salivary sample collection. Values oscillating between 0 and 8.1 pg/ml were 
considered as normal. Results: Salivary TNFα levels are 2 to 5 times higher in RAS patients than those of healthy 
patients. Conclusions: TNFα has a possible implication in the RAS etiology and it may also have an important role 
in the search of new treatments for this disease.
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Introduction
Recurrent aphthous stomatitis (RAS) is one of the 
most common diseases of the oral mucosa (1-3). A high 
number of research works have been carried out try-
ing to discover the cause of this prevalent disease. Nev-
ertheless, the etiology of RAS still remains unknown 
(1-3). Different authors are in controversy about the 
complex pathogenesis of the disease (1-3). One of the 
most discussed aspects is the exact role of different pre-
disposing factors such as genetic, immunologic, micro-
biologic, alimentary, hormonal, emotional or traumatic 
factors. Actually there is not a definitive explanation for 
the pathogenesis of RAS able to justify the implication 
of all of them (1-3).
The most accepted hypothesis about the etiology of 
the disease among the authors is based on the exist-
ence of a predisposition is some patients with a light 
immunitary alteration of a possible genetic origin. In 
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such patients, the presence of a local and/or systemic 
stimulation causes the transformation of oral mucosal 
cells into the target of the uncontrolled action of lym-
phocytes, monocytes and neutrophils. This would lead 
to the destruction of oral mucosal cells, the liberation of 
acute inflammation mediators and the development of 
an aphthous ulcer (4-6).
The ulcerative process is initiated by an unknown an-
tigenic stimulation of the mucosal keratinocytes which 
leads to t-lymphocyte stimulation, the liberation of 
citokynes such as TNF-α and different interleukins, and 
the migration of other lymphocytes, neutrophils and 
Langerhans cells. This also leads to an overexpression 
of Vascular Cell Adhesion Molecules (VCAM-1, Selec-
tine E) and Intercellular Adhesion Molecules (ICAM-1) 
causing the accumulation of lymphocytes and the lo-
cal lymphocytic invasion of the epithelium. Some cy-
tokines like TNF-α could stimulate the expresión of ma-
jor histocompatibility complex class I and II antigens 
in epithelial basal cells. These cells are recognized by 
t-lymphocites triggering a citotoxic response and caus-
ing the ulceration of the mucosa (4-6).
At present, TNFα is considered to be one of the most 
important cytokines implied in the development of new 
lesions in RAS patients. Several studies (7,8) have re-
ported an increase in salivary and serological TNFα, 
specially during the active phase of the disease. Nev-
ertheless, the actual cause of this increase has not been 
clarified to date. In the present work we have tried to 
confirm whether salivary TNFα is increased during the 
acute phase of RAS in patients in our vicinity.
Materials and Methods
The present study was carried out on 20 randomly se-
lected patients previously diagnosed with RAS. All of 
them were selected from the Oral Medicine Depart-
ment and Dental School of the University of the Basque 
Country. To set up a control group, 10 healthy patients 
were also randomly selected. All the patients signed an 
informed consent.
After formal signing and consent, in all of them a sali-
vary TNFα measurement was performed in samples of 
whole non stimulated saliva. Samples were obtained 
asking the patient to spit into a calibrated test tube dur-
ing five minutes. All the samples were collected between 
9 and 12 A.M. and after one our or more time since the 
last food intake. At this moment all the patients present-
ed active lesions in ulcerative phase.
After cooling for 10 minutes, the samples were fro-
zen (-25ºC) and processed.  TNFα determination was 
carried out employing immunoassay and quimiolumi-
niscence techniques. The Immulite-TNFα® test (Di-
agnostic Product Corporation, Dipesa SA, Spain) was 
employed for the measurement of  TNFα levels.
The salivary samples were cultivated in the presence of 
specific anti-TNFα antigen alter a controlled defrost and 
centrifugation. The levels of TNFα were determined 
with an automatic analysis unit Inmulite 2000® (Diag-
nostic Product Corporation, Dipesa SA, Spain) after the 
application of a quimioluminiscent substrate. Values 
between 0 and 8,1 pg/ml were considered within a nor-
mality range (7,11).
Results
The mean level of salivary TNFα was 53,6 pg/ml (range 
35,1-111) in RAS patients and 26 pg/ml (range 10,2-36,9) 
in control group. Statistically salivary TNFα levels were 
significantly higher (p≤0,01) in RAS patients. Tables 1,2 
and figure 1 show in detail the results of the analyses in 
both groups of patients.
Patients EAR TNFĮ (pg/ml) 
Sample 1 35,4 
Sample 2 38,6 
Sample 3 35,1 
Sample 4 45,1 
Sample 5 80,8 
Sample 6 111 
Sample 7 56,9 
Sample 8 42,3 
Sample 9 71,4 
Sample 10 78,8 
Sample 11 39,5 
Sample 12 42,5 
Sample 13 43,7 
Sample 14 36,9 
Sample 15 39,6 
Sample 16 55,7 
Sample 17 49,6 
Sample 18 50 
Sample 19 43 
Sample 20 76 
Table 1. Salivary TNFα levels in RAS patients.
Control Samples TNFĮ (pg/ml) 
Control 1 29,6 
Control 2 26,7 
Control 3 17,3 
Control 4 10,2 
Control 5 31,8 
Control 6 27,6 
Control 7 22,4 
Control 8 30,3 
Control 9 27,5 
Control 10 36,9 

Table 2.  Salivary TNFα levels in control patients.
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Discussion
TNF is a proinflammatory cytokine found in patients 
with cachexia and also whe studying the hemorrhagic 
necrosis in animal and human neoplasms (12,13). This 
cytokine is produced by monocytes, lymphocytes, NK 
cell and even by some human tumoral cells. The TNF 
also acts as a mediator of endotoxic shock and plays 
an important role in some autoimmune diseases, cer-
tain kinds of meningitis, HIV infection and cachexia 
(12,13). 
The exact role that TNF plays in the etiology or RAS is 
not well-known. Its contribution to the pathogenesis of 
the disease is borne out by two facts: high levels of TNF 
are detected in the first stages of oral ulcerations and 
some drugs like thalidomide or pentoxifylline with an 
anti-TNF action, have a high efficacy in the treatment of 
RAS and other ulcerative diseases such as Adamantia-
des-Behçet disease (7,14-17). 
Different authors (7,8) have observed increased levels 
of  TNFα in serum and in saliva of RAS patients, es-
pecially in the active phase of the disease. In our study, 
salivay TNFα was 2 to 5 times higher in patients with 
active lesions of RAS compared with controls. This re-
sult underlines the importance of this cytokine in the 
pathogenesis of RAS.
The complex pathogenesis of RAS is probably initiated 
by an endogenous or exogenous antigenic stimulation 
of oral mucosal keratinocytes. This causes the produc-
tion of different interleukins by stimulation of oral lym-
phocytes. TNFα is one of these interleukins of a great 
importance in the beginning of the inflammatory proc-
ess. This stimulation is the first step of a multistage 
process which lead to the activation f cytotoxic t-cells 
and neutrophils, the necrosis of the epithelium and fi-
nally the development of an aphthous lesion.
Fig. 1. Salivary  TNFα in RAS patients and control patients.
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Graphic 1: Salivary TNFĮ in RAS patients and control patients
Research workers in this field have demonstrated effi-
cacy in the prevention and treatment of RAS with some 
drugs that are able to reduce the production of TNF 
such as levamisol, thalidomide or pentoxifylline (14-
17). Probably their efficacy in the treatment of RAS is 
based in this inhibitory action.
There is not a definitive therapy for RAS and certain of 
drugs used in the treatment also have severe secondary 
effects. The search for new drugs with a more specific 
TNF inhibitory action and less side effects could be a 
new approach in the treatment of this disease in the fu-
ture.
Guimaraes and cols. (18) have related the high produc-
tion of some cytokines, such as TNFα, IL-1, IL-10 or 
IL-6 in RAS patients to some genetic polymorphisms. 
This fact could explain the family history frequently 
observed in some RAS patients.
Salivary determination is an easy and safe process that 
allows to measure the TNFα level modification in the 
same patient in different moments. A sample of 0.2 ml. 
of saliva is enough to make this determination.
We have not found other studies in the literature that 
determine the normal range in the salivary TNFα as-
sessment. In most of the research papers reviewed (7,11) 
serological normal range is employed (0-8,1 pg/ml). 
However, we think that this range should be reexamined 
for salivary samples.
The development of new drugs specifically designed to 
block the TNFα could be a new approach in the treat-
ment of RAS, with a higher efficacy and safety com-
pared with those used at present (17,19,20).
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